Key Takeaways
💸 Dividend yield sits at a modest 0.12%, but Ensign has now extended its dividend growth streak to 18 consecutive years, supported by a payout ratio of just 4.32% that leaves enormous room for future increases.
💰 Operating cash flow for the trailing twelve months reached $564.3 million, with $281.2 million in free cash flow, reflecting a business that continues to fund its own growth with disciplined internal generation.
📊 Five analysts covering the stock carry a mean price target of $220.40, implying modest upside from the current price of $212.39, with targets ranging from $210 to $230.
📈 Revenue crossed $5 billion on a trailing basis, net income rose to $344 million, and earnings per share came in at $5.83, each representing meaningful progress from a year ago.
Updated 2/25/26
Ensign Group (ENSG) operates hundreds of skilled nursing, assisted living, and rehabilitative care facilities across the U.S., supported by a decentralized model that puts operational control in the hands of local leadership. Backed by consistent revenue growth, rising earnings, and an 18-year streak of dividend increases, the company continues to expand its footprint through disciplined acquisitions while maintaining a strong balance sheet.
The management team, led by CEO Barry Port, has prioritized financial stability and operational efficiency over aggressive growth. With the stock trading near its 52-week high, steady free cash flow, and a history of navigating regulatory and labor-related challenges, Ensign offers a dependable profile for long-term investors seeking sustainable performance.
Recent Events
Ensign has continued its steady expansion campaign heading into 2026, pursuing bolt-on acquisitions in its core skilled nursing and assisted living segments at a pace consistent with recent years. The company has added multiple new operations across its target markets, each folded into its decentralized framework where local operators carry the day-to-day responsibility for clinical and financial results. This approach has become the defining feature of Ensign’s growth story, and it continues to attract attention from analysts and investors alike.
On the financial side, trailing twelve-month revenue has now surpassed $5 billion, a milestone that reflects years of compounding organic growth layered on top of a consistent acquisition cadence. Net income reached $344 million on a trailing basis, and earnings per share of $5.83 represent a meaningful step forward from prior periods. The company’s return on equity stands at 16.89%, which is a respectable figure for a capital-intensive healthcare operator.
The most recent quarterly dividend of $0.065 per share was paid out in December 2025, representing a fresh increase from the $0.063 per share paid through most of 2025 and marking the latest chapter in an 18-year streak of consecutive annual increases. The December raise was modest but deliberate, consistent with how management has always approached the dividend: steady, predictable, and reflective of genuine underlying strength rather than a gesture toward income investors.
Key Dividend Metrics
📈 Forward Dividend Yield: 0.12%
💰 Annual Dividend Rate: $0.26
🧮 Payout Ratio: 4.32%
📆 Dividend Growth Streak: 18 years
🧷 Most Recent Quarterly Dividend: $0.065
📊 Last Ex-Dividend Date: December 31, 2025
💸 Last Payment Date: December 31, 2025
Dividend Overview
The yield at 0.12% is not the reason anyone buys Ensign for income today. That is a straightforward fact. But the dividend here is a signal rather than a paycheck, and what it signals is worth paying attention to. The company generates well over half a billion dollars in operating cash flow annually, carries a payout ratio of just 4.32%, and has raised its dividend every single year for 18 consecutive years. That combination tells you everything about how management views capital stewardship.
The most recent quarterly payout of $0.065 represents a step up from the $0.063 rate that held steady through the first three quarters of 2025. On an annualized basis, the dividend now runs at $0.26 per share. With earnings per share at $5.83, the company is returning a fraction of its profits to shareholders via the dividend while retaining the vast majority for reinvestment and acquisitions. That architecture is intentional and it works.
Operating cash flow of $564.3 million covers the dividend many times over, and free cash flow of $281.2 million provides additional comfort. Ensign’s cash engine remains intact and growing, which is the most important thing a dividend investor needs to see beneath a low-yield stock in a compounding phase.
Dividend Growth and Safety
The 18-year dividend growth streak is the centerpiece of the income story here. Each year, without exception, Ensign has found a way to increase the payout. The increases are not dramatic in dollar terms, but they have been consistent and they have come through everything: a global pandemic, labor market disruptions, regulatory uncertainty, and multiple cycles of healthcare reimbursement reform. That kind of consistency is genuinely rare.
Looking at the recent dividend history, the progression tells a clear story. Payments held at $0.058 per quarter through most of 2023 before stepping up to $0.060 in the fourth quarter. That rate persisted through the first three quarters of 2024, then moved to $0.063 in the fourth quarter of 2024 and held through the third quarter of 2025 before the latest increase to $0.065 in December 2025. Each step is small, but the direction has never reversed.
The safety profile is exceptional. With a payout ratio of just 4.32%, there is virtually no scenario in which a normal cyclical downturn would threaten the dividend. Even if earnings declined significantly, the company could sustain current payouts with ease. For investors who plan to hold for five to ten years and let the compounding do its work, Ensign’s dividend represents one of the most durable growth commitments in the healthcare services sector.
Chart Analysis
Ensign Group’s chart tells a compelling recovery story over the past twelve months. Shares bottomed near $119.79 at the 52-week low and have since staged a remarkable run to the current price of $212.39, representing a gain of roughly 77% from that trough. The stock is now pressing against its 52-week high of $214.41, sitting just 0.94% below that ceiling. That kind of price trajectory from low to high reflects a sustained rerating of the business rather than a short-term speculative pop, and it signals that institutional buyers have been consistently accumulating shares throughout the move.
The moving average structure is unambiguously constructive. ENSG trades well above both its 50-day moving average of $184.40 and its 200-day moving average of $168.95, with the 50-day sitting above the 200-day in what technicians call a golden cross formation. That alignment confirms the intermediate and long-term trends are pointed in the same direction, and the distance between current price and both averages suggests the uptrend has had real durability rather than being a recent spike. For dividend investors who take a multi-year ownership view, a well-ordered moving average stack like this one provides a degree of technical confidence that the underlying business momentum is being reflected in price.
The RSI reading of 81.06 is the one area that warrants attention. A reading that far above the conventional overbought threshold of 70 indicates that buying momentum has been intense and that the stock is stretched in the near term. This does not automatically mean a reversal is imminent, as strong trending stocks can remain overbought for extended periods, but it does suggest that new buyers entering at current levels may face a period of consolidation or modest pullback before the next leg higher. A cooling in RSI toward the 55 to 65 range would actually represent a healthier setup for initiating or adding to a position.
For dividend-focused investors, the technical picture is broadly positive but calls for some patience on entry timing. The trend is clearly intact, the golden cross provides a solid structural foundation, and the proximity to a 52-week high reflects genuine fundamental strength being rewarded by the market. The elevated RSI simply suggests there is no urgency to chase the stock at this precise moment. Investors already holding shares have little reason for concern, while those looking to establish a new position may find a more attractive entry point if the stock digests its recent gains over the coming weeks.
Cash Flow Statement
Ensign Group’s cash generation has been one of the more compelling parts of the dividend story here. Operating cash flow climbed from $272.5 million in 2022 to $376.7 million in 2023, dipped modestly to $347.2 million in 2024, and then surged to $564.3 million in 2025, a figure that also represents the TTM reading. Free cash flow followed a similar arc, rising from $185.0 million in 2022 to $270.5 million in 2023, pulling back to $188.9 million in 2024 as capital expenditures absorbed more of the operating base, and then rebounding sharply to $370.7 million in 2025. The TTM free cash flow of $281.2 million reflects a more conservative trailing calculation but still sits comfortably above what the company needs to fund its dividend, which currently costs shareholders a relatively modest amount of capital on an annualized basis. That gap between dividend obligations and free cash flow production gives Ensign substantial room to continue raising its payout without straining the balance sheet.
Looking at the full arc from 2022 through 2025, the trajectory here is genuinely constructive for income investors. The 2024 free cash flow dip to $188.9 million was largely a reflection of elevated reinvestment activity as Ensign continued acquiring and integrating skilled nursing and senior living facilities, which is consistent with the company’s decentralized growth model rather than a sign of operational deterioration. The recovery to $370.7 million in free cash flow in 2025 confirms that those reinvestment years tend to translate into higher earnings power over time. Operating cash flow growing from $272.5 million to $564.3 million over just three years represents more than a doubling of the company’s cash generation capacity, which speaks to both volume growth through acquisitions and improving margin execution at the facility level. For dividend growth investors, a business that can double its operating cash flow in three years while maintaining a conservative payout ratio is precisely the kind of compounder that supports a long runway of annual dividend increases.
Analyst Ratings
Five analysts currently cover Ensign Group, and the consensus price target distribution reflects a stock that the Street views as fairly valued but still carrying incremental upside from current levels. The mean price target sits at $220.40, with the low end of the range at $210 and the high end at $230. At the current price of $212.39, shares are trading just above the low target and roughly $8 below the consensus mean, suggesting the analyst community sees modest room for further appreciation without projecting a dramatic re-rating.
The tight range of targets from $210 to $230 is itself informative. It implies a relatively high degree of consensus about Ensign’s near-term earnings trajectory and valuation ceiling, which is not surprising given the predictable nature of the company’s revenue model and the consistent execution the management team has demonstrated over many years. Analysts covering the stock have generally maintained constructive postures, citing Ensign’s decentralized operating model, its track record of successful acquisitions, and the resilience of its skilled nursing volumes as the primary pillars of the bull case. The risks flagged most consistently include labor cost pressure and Medicaid reimbursement uncertainty at the state level, both of which are sector-wide concerns rather than company-specific weaknesses.
Earnings Report Summary
Strong Start to the Year
Ensign’s most recently reported full trailing twelve-month results reflect a company that has continued to execute at a high level across all of its key financial metrics. Revenue crossed $5.06 billion, representing continued double-digit growth on a year-over-year basis. Net income came in at $344 million, and earnings per share reached $5.83, both of which mark meaningful improvements from prior periods. The profit margin of 6.80% and return on equity of 16.89% reinforce that the growth is not just topline noise but is translating into genuine bottom-line improvement.
The company’s skilled nursing facilities have continued to carry significant operational weight. Utilization trends have remained favorable, with occupancy improvements at both established and newer facilities contributing to the revenue ramp. The company’s ability to improve performance at acquired facilities within a relatively short timeframe remains one of the most compelling aspects of the Ensign model, and the numbers continue to validate that capability.
Confident Guidance and Expansion
Management has consistently raised guidance as results have come in above expectations, reflecting genuine confidence in the trajectory of the business. The company’s acquisition pace has remained active, with new operations being added regularly across its target geographies. Each addition follows the same playbook: acquire, embed the decentralized leadership structure, improve operations, and let local teams drive performance. The financial results suggest this approach continues to work at scale even as the overall facility count grows.
Capital expenditures have increased alongside the revenue base, reflecting ongoing investment in both new and existing facilities. The growth in operating cash flow to $564.3 million gives the company ample room to fund this investment without relying on external financing, which has been a consistent feature of how Ensign manages its balance sheet through expansion cycles.
Leadership Commentary and What’s Next
CEO Barry Port has maintained a consistent message through recent periods: the company’s decentralized model is its most durable competitive advantage, and local leadership accountability is what drives clinical and financial outcomes. That philosophy has not changed, and it continues to differentiate Ensign from larger, more centrally managed healthcare operators. The tone from management heading into 2026 has remained measured and optimistic, focused on disciplined growth rather than headline-grabbing moves.
Looking ahead, Ensign is well positioned to sustain its acquisition cadence while continuing to improve performance at its existing base of operations. State-level Medicaid dynamics remain a variable worth monitoring, but the company’s geographic diversification across many states provides a natural buffer against any single policy shift. The combination of strong cash flow, a clean balance sheet, and an experienced leadership team leaves Ensign in a strong position as it heads further into 2026.
Management Team
Ensign Group’s leadership continues to be a standout feature, especially in an industry where operational missteps can be costly. Barry Port, who took over as CEO in 2019, has been with the company for many years and understands the business from the inside out. He comes from an operational background, and that focus is reflected in how the company runs today. The strategy centers around decentralization, putting decision-making power into the hands of local facility leaders rather than trying to manage everything from the top down.
That approach is not just theoretical. It has proven effective across different economic environments and has scaled well as the company’s facility count has grown. CFO Suzanne Snapper has played a key role in balancing Ensign’s growth ambitions with a strong financial foundation. The team around them is stable, experienced, and largely made up of long-tenured leaders who have been promoted internally. That continuity matters. It builds institutional knowledge and means decisions are informed by firsthand experience. Ensign does not try to grab attention with flashy projections or bold headlines. The leadership simply focuses on operating efficiently, maintaining strong margins, and growing in ways that make sense for the long term.
Valuation and Stock Performance
At $212.39, Ensign is trading near its 52-week high of $216.92 and has traveled a considerable distance from the 52-week low of $118.73. That move reflects genuine fundamental progress, with earnings growth, revenue scale, and cash flow expansion all validating the higher price level rather than simply reflecting multiple expansion. The trailing P/E of 36.43 is elevated relative to where the stock has historically traded, and it represents the primary valuation risk at the current entry point for new investors.
The price-to-book ratio of 5.49 against a book value per share of $38.71 also reflects a premium that the market is awarding to Ensign’s consistent execution and durable growth model. These are not distressed or even modestly valued multiples, and anyone buying today is paying up for a demonstrated track record. The question for prospective buyers is whether the 18-year dividend growth streak, the $564 million in operating cash flow, and the disciplined acquisition model justify that premium over time. For long-term holders who already own the stock near lower levels, the valuation simply reflects the wisdom of holding a quality compounder through a multi-year cycle.
With the analyst consensus target at $220.40, there is limited near-term upside implied by the Street, but also no broad expectation of a meaningful pullback. The stock’s beta of 0.87 suggests it moves with somewhat less volatility than the broader market, which is consistent with its defensive healthcare positioning. For investors with a long time horizon, the current valuation is demanding but not unreasonable given the underlying fundamentals, and the dividend growth story remains intact regardless of where the stock price moves in any given quarter.
Risks and Considerations
Ensign’s reliance on Medicare and Medicaid reimbursements remains the most prominent external risk. Any material change in federal or state funding policy could put pressure on revenue, and while the company’s geographic diversification across many states provides some buffer, a broad shift in reimbursement rates would affect the business regardless of how well it is managed operationally. This is not a company-specific vulnerability but rather a sector-wide reality that investors in healthcare services must accept as a permanent feature of the landscape.
Labor costs continue to challenge the sector broadly, and Ensign is not immune. Staffing shortages and wage inflation have pushed up operating expenses across skilled nursing operators, and while Ensign has demonstrated an ability to manage this through its local leadership model and operational discipline, a sustained period of tight labor markets could compress margins in ways that are difficult to offset through pricing or efficiency gains alone.
The company’s active acquisition program, while generally a strength, also introduces ongoing integration risk. Adding new facilities at a consistent pace requires management bandwidth and operational focus, and any meaningful misstep in the integration process could affect near-term results. Ensign’s track record here is strong, but history does not guarantee future outcomes, and the complexity of managing a large and growing portfolio of healthcare facilities should not be underestimated.
Finally, the current valuation at a trailing P/E of 36.43 leaves little margin for error. If earnings growth were to slow for any reason, whether from reimbursement pressure, labor cost escalation, or a more difficult acquisition environment, the multiple would likely compress and the stock could give back a meaningful portion of its recent gains. The dividend yield of 0.12% provides almost no cushion for that kind of price correction, which means investors in Ensign today are accepting valuation risk in exchange for the quality and consistency of the underlying business.
Final Thoughts
Ensign Group offers something rare in healthcare: a clear, repeatable model that has proven to work through different market conditions over nearly two decades. The leadership team is experienced, focused, and grounded in operational reality. Their decentralized approach is not just efficient, it is durable. It allows the company to scale without sacrificing local-level quality, and that is a big reason why results have stayed consistent even as the business has grown to more than $5 billion in annual revenue.
The dividend growth streak of 18 consecutive years is the income investor’s anchor here. The yield is small, but the commitment behind it is serious, and the cash flow base supporting it has never been stronger. The move from $0.063 to $0.065 per quarter in December 2025 was another modest but deliberate step in a long progression, and there is no reason based on current fundamentals to expect that progression to end.
The primary caveat at this price is valuation. Trading near its 52-week high with a P/E above 36, Ensign is not offering a wide margin of safety for new buyers. The risks are real, particularly around reimbursement policy and labor costs, and the current multiple leaves limited room for earnings disappointment. But for investors who already own the stock or who are building a position with a genuinely long time horizon, the fundamentals remain compelling and the compounding story is very much intact.
All in, Ensign continues to show what can be done when leadership, financial strength, and strategy align over a long period of time. It is not flashy, but it is steady. And in a space where consistency is genuinely hard to find, that continues to make all the difference.